MindMaze Therapeutics Announces Non-Core Asset Sale and Organizational Simplification
-
West must embrace 'national power' or face decline: Rubio
-
Kyiv 'cannot agree' to EU membership limiting food exports: minister
-
Shell refining margins reach record highs as wars hit supply
-
Arteta targets more Arsenal glory after signing new deal until 2030
-
Former Spain, Barca winger Pedro retires from football
-
Russell hit with Singapore grid penalty for taking new power unit
-
Arteta signs new Arsenal deal until 2030
-
Spotify expands audiobooks to more than 180 markets
-
Stocks decline as oil climbs on Mideast flareup
-
French-Japanese duo wins chemistry Nobel for solving molecular 'mystery'
-
Gauff says online abuse was 'draining' after China Open exit
-
England's Nations League surge helps heal World Cup wounds
-
As sector struggles, Porsche puts luxury ahead of volume
-
Mayor of opposition stronghold Izmir defects to Erdogan party
-
'It's personal': Fiji minister pushes better climate finance at pre-COP
-
Mertens beats Gauff to set up Swiatek clash at China Open
-
Russia glosses over dark Soviet past in reinvented museum
-
Benin full of pride at role in Messi's last dance
-
UK tax body opened probe into Man City in 2018: FT
-
France suspends stun grenade use at student protests ahead of PM speech
-
Yemen's Houthis claim new attacks on Saudi airports as conflict deepens
-
Indonesian court hears 'negligence' complaint against state over fires, haze
-
Germany factory production at highest level for 18 months
-
Rubio in Greece to urge against Western civilisation 'decline'
-
Thailand floods death toll rises to 60 since mid-September
-
Micron workers at Taiwan plant vote in favour of strike
-
US pushes Russia for information on plague reports
-
In 'The Social Reckoning,' Jeremy Allen White takes on Facebook's 'frightening' ambition
-
Myanmar leader lands in Malaysia for migrant return talks
-
Chip industry activists call for South Korea to recognise cancer cases
-
Indian central bank hikes rates for first time since 2023
-
Famine-scarred southern Madagascar braces for El Nino
-
US military on Okinawa face curfew, alcohol ban after murder case
-
How the EU regulates lobbyists
-
Fierce lobbying in EU over 'forever chemicals'
-
I.Coast refuge offers lifelong care for youngsters scorned as 'sorcerers'
-
Dodgers beat Braves and Padres avoid sweep in MLB playoffs
-
Indian central bank hikes rates for first time in more than 3 years
-
Mourning, war and elections as Israel marks October 7
-
Hotel Blacklist Launches New Accommodation Industry Risk Assessment Tool
-
Messi says Argentina retirement is 'saddest day of my career'
-
Bangladesh nuclear plant draws hope -- and worry
-
Oil rises and stocks fall as Hormuz worries flare
-
US beat Canada 1-0 to wrap up four-win international break
-
Pacific presses world for help 'surviving' climate change at pre-COP summit
-
Turkey, Australia's joint COP31 leadership raises doubts
-
Verstappen revival to be put to the test in steamy Singapore
-
For Turkish NGOs, COP31 offers rare space for action
-
US woman who survived botched execution is conscious, speaking: lawyers
-
Sleep, appetite, gene-editing experts contend for Nobel chemistry prize
MindMaze Therapeutics Announces Non-Core Asset Sale and Organizational Simplification
GENEVA, CH / ACCESS Newswire / June 2, 2026 / MindMaze Therapeutics Holding SA (SIX:MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today announced the sale of the U.S. and Canadian rights to RLF-OD032, a phenylketonuria program, as part of the Company's previously announced initiative to dispose of non-core assets and operations outside its core neurology focus. MindMaze Therapeutics will receive upfront cash consideration of USD 3 million, together with royalties on future net sales of RLF-OD032.
The Company also announced that it has executed term sheets relating to the disposal of substantially all remaining non-neurology legacy operations acquired through the business combination with Relief Therapeutics. These transactions follow a comprehensive portfolio review and are expected to further simplify the organization, enhance operational focus, and reduce the Company's cost base by approximately one-third. Subject to the execution of definitive agreements, the Company expects this organizational simplification initiative to be substantially completed during the third quarter of 2026.
Together with the recently announced CHF 8 million financing, proceeds from the RLF-OD032 sale will support the Company's strategic priorities in neurology, including commercial expansion and broader patient access to its neurotherapeutic platform.
About MindMaze Therapeutics
MindMaze Therapeutics (SIX: MMTX) is a global leader in scalable, precision neurotherapeutics, dedicated to redefining the recovery trajectory for patients around the world. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care from the acute hospital phase to outpatient treatment to home-based therapy. The company's FDA-cleared and CE-marked products are designed to address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson's disease, and other neurological disorders. With an extensive library of rigorous clinical validation and a robust R&D pipeline, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine.
For more information, visit www.mindmazetherapeutics.com.
Media & Investor Contacts
Investor Relations:
Jeremy Meinen, Chief Financial Officer
[email protected]
Media Inquiries:
VSC for MindMaze Therapeutics
[email protected]
DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
SOURCE: MindMaze Therapeutics Holding SA
View the original press release on ACCESS Newswire
W.Nelson--AT
